Navigating the Field of ERBB2-Positive Breast Cancer Treatment Options: Important Data in the Post-Trastuzumab Era

Description:,The diagnosis of human epidermal growth factor receptor 2-positive metastatic breast cancer has historically been associated with poor clinical outcomes. The use of monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates has impacted patient care. Novel targeted therapies and combinations of treatments are now used in practice, and pharmacists are well-positioned to assist in therapy selection. This activity will focus on updates in clinical practice guidelines and will review strategies for treatment selection and sequencing, potential drug resistance, and patient-specific considerations. Additionally, the faculty will review challenging patient cases to reinforce key principles and nuances with therapy.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Personalize treatment plans for a patient with human epidermal growth factor receptor 2 (ERBB2)-positive breast cancer based on disease- and patient-specific factors,• Determine optimal adjuvant treatment strategies for ERBB2-positive breast cancer,• Construct a plan for sequencing drug therapies for ERBB2-positive breast cancer, accounting for safety, efficacy, and patient specifics